CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 60 enrolled
Drug / intervention
RAD001drug
Likely dose
RAD001 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00529802
NCT00529802Phase 2Completed
CompareCT.gov

An Exploratory Study Evaluating FDG-PET as a Predictive Marker for mTOR Directed Therapy With RAD001 in Metastatic Renal Cell Cancer

University of Chicago·interventional·Posted Sep 14, 2007·Updated Apr 25, 2018

In Brief

A Phase 2 clinical trial evaluating RAD001 for Carcinoma, Renal Cell. Completed, enrolled 60 participants across 5 sites.

Detailed Summary

The purpose of this study is to learn if PET scanning can predict the degree of tumor shrinkage with the study drug RAD001 in subjects who have advanced renal cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Renal Cell
CountriesUnited States
CollaboratorsNovartis

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 14, 2007
Enrollment StartSep 1, 2007
Primary CompletionJul 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 18.8 years ago

Interventions

RAD001drug

take 2 tablets of RAD001 once a day by mouth (10 mg per day)